|
|
|
11-50 employees
View all
|
|
Biotechnology
|
|
Recludix is a leader in developing platform approaches to discover potent and selective inhibitors of challenging protein targets by integrating custom generated DNA-encoded libraries, massively parallel determination of structure activity relationships, and a proprietary screening tool to ensure selectivity. Recludix is employing this approach first in the development of SH2 domain inhibitors. Its most advanced programs are focused on Signal Transducer and Activator of Transcription (STAT) proteins -- STAT3 and STAT6 -- where abnormal activation is found in numerous cancer types, such as multiple leukemias and lymphomas, as well as inflammatory diseases, such as rheumatoid arthritis, asthma, atopic dermatitis inflammatory bowel disease, and others. The company is advancing another program with an undisclosed non-STAT SH2 domain target that also plays a significant role in both cancer and autoimmune diseases. For more information, please visit the company’s website at https://recludixpharma.com.
|
Recludix Pharma Email Formats | Example Email Formats | Percentage |
---|---|---|
{f}{last} | [email protected] |
75.00%
|
The widely used Recludix Pharma email format is {f}{last} (e.g. [email protected]) with 75.00% adoption across the company.
To contact Recludix Pharma customer service number in your country click here to find.
Find accurate personal emails, work emails and phone numbers for employees
Accelerate prospecting with instant access to 300M professionals from 30M companies with the right contact details.